Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax plus dose-intense rituximab vs dose-intense rituximab alone in previously untreated B-cell chronic lymphocytic leukemia
2009-012152-24Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of navitoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Progression-free survival. Started May 2010; status: terminated.
02
Drugs
navitoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2009-012152-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012152-24.